Abstract Women with BRCA1 pathogenic variants face high lifetime risks of breast and ovarian cancer, requiring complex risk-reducing decisions. We report a 35-year-old woman with node-negative triple-negative breast cancer who achieved a pathologic complete response after neoadjuvant chemotherapy and breast-conserving...
Archi Rungta, Anjana Anoop, Srushti Uthale et al.· Indian Journal of Medical an...· 0 citations
Carapenem resistance in India remains alarmingly high, primarily driven by NDM and OXA‐type carbapenemases, and optimised diagnostics, improved access to effective antimicrobials, robust antimicrobial stewardship, and national surveillance are critical to mitigate its growing clinical and public health impact.
A. Kapoor, Anuj Gupta, Bipinesh Sansar et al.· BioMed Research Internationa...· 0 citations
Findings underscore the importance of tumor biology over environmental factors in survival and highlight the need for early detection and novel therapeutic strategies in MM.
P. Majumdar, Sonal Tripathi, Paramita Paul et al.· SN Comprehensive Clinical Me...· 0 citations
KRAS-mutant NSCLC is transitioning from historically untargetable disease to a therapeutically actionable subset, and future progress hinges on resistance-directed combinations, biomarker-guided personalization, expansion to non-G12C mutants, and evaluation in earlier disease settings.
A. Kapoor, Bipinesh Sansar, Anuj Gupta et al.· Medical Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
